Nanospectra Biosciences
Nanospectra Biosciences, Inc.
About Nanospectra Biosciences
Nanospectra Biosciences, Inc. is a privately-held medical device company founded in 2002, operating out of Houston, Texas. The company was established based on intellectual property developed at Rice University. The foundational technology was invented by Dr. Naomi Halas, a nanoscientist at Rice University who created gold-silica nanoshells in 1997, and Dr. Jennifer West, a bioengineer at Duke University. Recognizing the potential for a nanoparticle-based cancer therapy, they co-founded Nanospectra around the year 2000 to bring the technology to clinical use. Their work has since been recognized with awards, including being named Inventors of the Year by the State Bar of Texas.
Nanospectra is focused on the commercialization of nanoparticle-based therapies for the precise thermal destruction of solid tumors. The company's business model centers on developing and bringing to market its proprietary medical device, the AuroLase® Therapy, for clinical use in oncology. Its revenue generation is expected from the sale of this device and through strategic partnerships and licensing agreements, such as its exclusive commercialization partnership with Enovis for veterinary medicine. To date, the company's development has been supported through a combination of private equity investments, corporate partnerships, and grants. Nanospectra has raised a total of $24.5 million over 20 funding rounds, with a notable Series B round led by strategic investor Sirtex Medical.
The company's core product is AuroLase® Therapy, an ultra-focal ablation treatment designed to selectively destroy cancerous tissue while minimizing damage to adjacent healthy tissue. The therapy involves two main components: intravenously delivered AuroShell® particles (gold-silica nanoshells) and a near-infrared laser. These nanoshells, approximately 150nm in size, are designed to accumulate in solid tumors through their leaky vasculature. Following infusion, a clinician uses MRI/ultrasound fusion imaging to identify the lesion and guide a fiber optic probe to the tumor site. A near-infrared laser, which can pass harmlessly through human tissue, is then used to illuminate the tumor. The AuroShell particles are specifically tuned to absorb this light energy, converting it into heat, which thermally destroys the tumor cells and their blood supply. This targeted approach aims to reduce the significant side effects associated with traditional cancer treatments like surgery and radiation, particularly for prostate cancer.
Nanospectra's primary clinical focus is on treating low to intermediate-risk localized prostate cancer. The company has completed enrollment for a multi-center pivotal study to support its submission for FDA marketing clearance. This follows a successful first-in-human feasibility study. The AuroLase Therapy device has received 510(k) clearance from the FDA for use with compatible lasers in cleared applications. While initially exploring applications in head and neck cancers, the company has concentrated on prostate cancer, where the therapy offers a middle ground between active surveillance and radical treatments.
Source: Dealroom company dataNews
Open roles
Nanospectra Biosciences in the Houston ecosystem
The Nanospectra Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Sirtex Medical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanospectra Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanospectra Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

